DSN LINK STABLECARRIER WAVE LOCKORBITAL INDEX HOTSIGNAL CLOCK SYNCLOW NOISE FLOORFRAME BUFFER ONLINE
Loading
DSN LINK STABLECARRIER WAVE LOCKORBITAL INDEX HOTSIGNAL CLOCK SYNCLOW NOISE FLOORFRAME BUFFER ONLINE
Loading portal core
5 articles
Eli Lilly says a high dose of Verve’s gene-editing therapy lowered cholesterol by 62% in an early clinical trial.
New research suggests a daily GLP-1 pill could help maintain results achieved with semaglutide or tirzepatide.
A single investor just turned $1 million into $385 million—without a drug, a trial, or even a double-digit headcount.
Insilico Medicine’s AI platform has never produced an FDA-approved drug—but Eli Lilly just wagered up to $2.75 billion on its potential.
CVS faces a settlement over manipulated insulin prices, potentially saving Americans $7 billion.
